medigene ag fse isin prime standard publicly listed biotechnology company headquartered martinsried near munich medigene working development immunotherapies enhance cell activity solid first product candidates clinical development medigene german biotechnology company founded spinoff munich gene center company went public initial public offering frankfurt stock following years medigene acquired several biotechnology companies including neurovir avidex received regulatory approval cancer drug eligard medigenes product veregen became first fdaapproved biopharmaceutical german biotech company united medigene underwent strategic repositioning sale eligard endotag company shifted focus immunooncology acquisition trianta immunotherapies renamed medigene immunotherapies medigene started phase iii clinical trial dc vaccine treat acute myeloid leukemia following year company entered strategic partnership bluebird bio cancer medigene disposed us rights veregen expanded partnership bluebird bio company also started phase iii study drug acute myeloid leukemia myelodysplastic medigene partnered roivant sinovant launch cytovant sciences focuses developing cellular therapies asia year medigene sold remaining rights inventories company published topline data dc vaccine trial published topline data phase iii study medigene entered comprehensive research development partnership german corporation company article stub help wikipedia expanding httpsenwikipediaorgwikimedigene